US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

F/m Emerald Life Sciences Innovation ETF

47.80

+0.35490.75%

Volume:3K

Turnover:147.73K

Market Cap:131.77M

PE:- -

High:48.06

Open:47.84

Low:47.78

Close:47.44

52wk High:48.78

52wk Low:27.34

Shares:2.76M

Float Shares:2.76M

Volume Ratio:0.73

T/O Rate:0.11%

Dividend:- -

Dividend Rate:- -

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Sector Update: Healthcare

MT Newswires Live

Guardant Health Loses $245.2 Million Patent Infringement Case

MT Newswires Live

Regenxbio reports FDA placed clinical hold on RGX-121

Twinstrand: Court Awards Co and Uw over $245.2 Mln in Damages, Accrued Royalties & Interest for Infringement That Occurred Through May 31, 2026

THOMSON REUTERS

Twinstrand: Delaware Court Enters Judgment on Aug. 21 in Favor of Co & University of Washington in Patent Infringement Suit Against Guardant Health

THOMSON REUTERS

Twinstrand: Under Judgment, Guardant Health Must Provide Co & Uw with Quarterly Accounting of All U.S. Sales of 11 Guardant Health Products & Services

THOMSON REUTERS

Twinstrand: Court Preserves 2023 Willful Infringement Verdict & Orders 6% Royalty on Sales of 11 Guardant Health Products & Services

THOMSON REUTERS

Travere Therapeutics (TVTX) Is Up 6.1% After FILSPARI Beats FSGS Launch Expectations

Simply Wall St.

Regeneron’s Pasatru granted FDA approval for FOP

Is Spyre Therapeutics (SYRE) Fully Priced After Its SPY772 Program And SKYLIGHT Trial Launch?

Simply Wall St.

Glenmark Wins U.S. FDA Nod for Generic Flonase Nasal Spray

Telix outlines H1 2026 progress in radiopharmaceutical and precision medicine units

Travere Therapeutics Director Gary A. Lyons Disposes of USD 629,150 in Common Shares

Femasys announces FDA approval of FemBloc modular premarket approval application

Soccer-Sheffield United's Ex-Owners Winds up Company Which Bought Club

Guardant Health Director Tariq Musa Disposes of 116 Common Shares Worth $18,148.2

Amylyx Phase 3 data support FDA approval, says Citi

Guardant Health (GH) Back In Focus As New Approvals Put Valuation To The Test

Simply Wall St.

Genprex selects manufacturing organization for diabetes gene therapy

Has Cogent Biosciences (COGT) Run Too Far After Wider Losses?

Simply Wall St.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/stock/LFSC/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"LFSC","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LFSC\",,,,,undefined,":{"symbol":"LFSC","market":"US","secType":"STK","nameCN":"F/m Emerald Life Sciences Innovation ETF","latestPrice":47.7953,"timestamp":1787342400000,"preClose":47.4404,"halted":0,"volume":3080,"delay":0,"changeRate":0.00748096559050937,"floatShares":2757035,"shares":2757035,"eps":0,"marketStatus":"Pre-Mkt","change":0.3549,"latestTime":"08-24 09:04:17 EDT","open":47.84,"high":48.06,"low":47.78,"amount":147728.966,"amplitude":0.005902,"askPrice":76.47,"askSize":200,"bidPrice":46.26,"bidSize":11,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1787578200000},"marketStatusCode":1,"adr":0,"exchange":"NASDAQ","adjPreClose":47.7953,"sharesOutstanding":2657035,"nav":47.42,"aum":130738599.7,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":47.9,"preClose":47.7953,"latestTime":"19:30 EDT","volume":7,"amount":334.5671,"timestamp":1787355006986,"change":0.1047,"changeRate":0.002191,"amplitude":0},"volumeRatio":0.7335079553807967},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LFSC\",,,,,undefined,":{"symbol":"LFSC","floatShares":2757035,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.7335079553807967,"shares":2757035,"dividePrice":0,"high":48.06,"amplitude":0.005902,"preClose":47.4404,"low":47.78,"week52Low":27.3402,"pbRate":"--","week52High":48.78,"institutionHeld":0,"latestPrice":47.7953,"eps":0,"divideRate":0,"volume":3080,"delay":0,"ttmEps":0,"open":47.84,"prevYearClose":36.6147,"prevWeekClose":47.7953,"prevMonthClose":45.55,"prevQuarterClose":45.2033,"fiveDayClose":47.0833,"twentyDayClose":45.1004,"sixtyDayClose":39.0706},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LFSC\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LFSC\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LFSC\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"LFSC\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2661279439","title":"Sector Update: Healthcare","url":"https://stock-news.laohu8.com/highlight/detail?id=2661279439","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661279439?lang=en_us&edition=fundamental","pubTime":"2026-08-24 20:58","pubTimestamp":1787576324,"startTime":"0","endTime":"0","summary":"Healthcare stocks were mixed pre-bell Monday, with the State Street Health Care Select Sector SPDR ETF  0.4% higher and the iShares Biotechnology ETF  down 0.2%,Guardant Health  lost a $245.2 million patent infringement lawsuit filed by TwinStrand Biosciences and the University of Washington, TwinStrand said. Guardant Health stock was down more than 1% premarket.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["HELX","BK4588","BK4535","IE00B3QW5Z07.USD","GH","XBI","BK4585","BK4135","GNMX","LU0109394709.USD","LU1894683348.USD","BK4196","LU0320765992.SGD","LU1894683264.USD","PTH","STT","BK4137","BK4551","EKG","LFSC","GDOC","IE0034235188.USD","BK4581","LU0128526141.USD","IBB","XLV","GNOM","LABU","LU0889565916.HKD","IE00BGHQF748.EUR","LU1883839398.USD","FFOX","LU0029874061.USD","FDN","LU0061475181.USD","HCSG","BK4550","IE00B64PRP62.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661752702","title":"Guardant Health Loses $245.2 Million Patent Infringement Case","url":"https://stock-news.laohu8.com/highlight/detail?id=2661752702","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661752702?lang=en_us&edition=fundamental","pubTime":"2026-08-24 19:51","pubTimestamp":1787572313,"startTime":"0","endTime":"0","summary":"Guardant Health  lost a $245.2 million patent infringement lawsuit filed by TwinStrand Biosciences and the University of Washington, TwinStrand said Monday.The final judgment, issued Friday, maintains a November 2023 jury verdict finding that Guardant Health willfully infringed two patents underlying TwinStrand's Duplex Sequencing technology in 11 royalty-bearing products and services, and awards TwinStrand and the University of Washington damages, accrued royalties and interest for infringement through May 31, 2026, the company said.The court ordered Guardant Health to pay a 6% royalty on sales of the covered products and services from June 1, 2026 until the expiration of the patents on March 15, 2033, the company said.Guardant is also required to provide quarterly accounting of US sales of the covered products and services, TwinStrand said.Guardant did not iimmediately reply to MT Newswires' request for comment.Shares of Guardant were down 1.6% in recent premarket trading.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["HELX","BK4585","GNOM","GH","BK4551","GNMX","LFSC","BK4196","EKG","LU0109394709.USD","LU0889565916.HKD","BK4588","GDOC","PTH","LU0320765992.SGD","BK4535","FFOX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661627309","title":"Regenxbio reports FDA placed clinical hold on RGX-121","url":"https://stock-news.laohu8.com/highlight/detail?id=2661627309","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661627309?lang=en_us&edition=fundamental","pubTime":"2026-08-24 19:20","pubTimestamp":1787570406,"startTime":"0","endTime":"0","summary":"Regenxbio (RGNX) provided an update on its investigational gene therapy, RGX-121, for the treatment of Mucopolysaccharidosis type II, also known as...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/regenxbio-reports-fda-placed-clinical-hold-on-rgx-121-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/regenxbio-reports-fda-placed-clinical-hold-on-rgx-121-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4505","GNOM","IBB","BK4585","SYNB","FBT","RGNX","TBXU","CNCR","IBBQ","LFSC","LABU","BK4588","BK4563"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661727387","title":"Twinstrand: Court Awards Co and Uw over $245.2 Mln in Damages, Accrued Royalties & Interest for Infringement That Occurred Through May 31, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2661727387","media":"THOMSON REUTERS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661727387?lang=en_us&edition=fundamental","pubTime":"2026-08-24 19:00","pubTimestamp":1787569200,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260824:nP8N3M60G7:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LFSC","EKG","BK4551","PTH","GNMX","GH","LU0889565916.HKD","LU0109394709.USD","BK4585","BK4588","LU0320765992.SGD","BK4196","HELX","FFOX","GNOM","BK4535","GDOC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661327802","title":"Twinstrand: Delaware Court Enters Judgment on Aug. 21 in Favor of Co & University of Washington in Patent Infringement Suit Against Guardant Health","url":"https://stock-news.laohu8.com/highlight/detail?id=2661327802","media":"THOMSON REUTERS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661327802?lang=en_us&edition=fundamental","pubTime":"2026-08-24 19:00","pubTimestamp":1787569200,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260824:nP8N3M60G7:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PTH","LU0109394709.USD","LU0320765992.SGD","LU0889565916.HKD","BK4551","GH","GNMX","GNOM","LFSC","EKG","BK4588","GDOC","FFOX","BK4196","BK4535","HELX","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661278025","title":"Twinstrand: Under Judgment, Guardant Health Must Provide Co & Uw with Quarterly Accounting of All U.S. Sales of 11 Guardant Health Products & Services","url":"https://stock-news.laohu8.com/highlight/detail?id=2661278025","media":"THOMSON REUTERS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661278025?lang=en_us&edition=fundamental","pubTime":"2026-08-24 19:00","pubTimestamp":1787569200,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260824:nP8N3M60G7:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LFSC","GH","BK4588","HELX","LU0889565916.HKD","GNOM","LU0109394709.USD","BK4535","EKG","GNMX","FFOX","BK4196","LU0320765992.SGD","GDOC","PTH","BK4585","BK4551"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661273336","title":"Twinstrand: Court Preserves 2023 Willful Infringement Verdict & Orders 6% Royalty on Sales of 11 Guardant Health Products & Services","url":"https://stock-news.laohu8.com/highlight/detail?id=2661273336","media":"THOMSON REUTERS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661273336?lang=en_us&edition=fundamental","pubTime":"2026-08-24 19:00","pubTimestamp":1787569200,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260824:nP8N3M60G7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0889565916.HKD","GDOC","HELX","GNMX","EKG","FFOX","GNOM","LU0320765992.SGD","GH","BK4535","LFSC","LU0109394709.USD","BK4585","BK4196","PTH","BK4551","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660323865","title":"Travere Therapeutics (TVTX) Is Up 6.1% After FILSPARI Beats FSGS Launch Expectations","url":"https://stock-news.laohu8.com/highlight/detail?id=2660323865","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660323865?lang=en_us&edition=fundamental","pubTime":"2026-08-20 21:32","pubTimestamp":1787232770,"startTime":"0","endTime":"0","summary":"Travere Therapeutics recently reported that FILSPARI’s launch in FSGS is outperforming expectations with broad physician demand across a U.S. pool of more than 30,000 biopsy-confirmed patients.\nThe company is also pushing its rare disease pipeline forward with a Phase III trial of pegtibatinase in classical homocystinuria and adding civorebrutinib for multiple renal indications affecting roughly 130,000 patients, underscoring a widening kidney-focused franchise.\nWe’ll now examine how...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tvtx/travere-therapeutics/news/travere-therapeutics-tvtx-is-up-61-after-filspari-beats-fsgs","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tvtx/travere-therapeutics/news/travere-therapeutics-tvtx-is-up-61-after-filspari-beats-fsgs","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LFSC","BK4139","TVTX","FSGS","FFTY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660287604","title":"Regeneron’s Pasatru granted FDA approval for FOP","url":"https://stock-news.laohu8.com/highlight/detail?id=2660287604","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660287604?lang=en_us&edition=fundamental","pubTime":"2026-08-20 21:20","pubTimestamp":1787232025,"startTime":"0","endTime":"0","summary":"The U.S. Food and Drug Administration has approved Pasatru to reduce new heterotopic ossification and reduce clinician-assessed disease flare-ups i...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/regenerons-pasatru-granted-fda-approval-for-fop-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/regenerons-pasatru-granted-fda-approval-for-fop-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BMED","GNMX","TBXU","IEIH","IBB","MRNY","NVIB","XLVX","BK4588","LABU","GDOC","MEDI","LFSC","FRTY","IYH","RSPH","BK4585","TECB","MRNX","BBP","SYNB","IDNA","PINK","PSCH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660406265","title":"Is Spyre Therapeutics (SYRE) Fully Priced After Its SPY772 Program And SKYLIGHT Trial Launch?","url":"https://stock-news.laohu8.com/highlight/detail?id=2660406265","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660406265?lang=en_us&edition=fundamental","pubTime":"2026-08-20 13:34","pubTimestamp":1787204046,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics stock reacts to new SPY772 program and SKYLIGHT trial launch\nSpyre Therapeutics (SYRE) is in focus after the company launched its SPY772 combination program and began SKYLIGHT, a Phase 2 proof of concept trial in Hidradenitis Suppurativa.\nBoth efforts target dual inhibition of TL1A and IL-17A/F in moderate to severe HS. The approach uses SPY072 alongside background bimekizumab therapy for around 150 adult participants.\nSee our latest analysis for Spyre Therapeutics.\nSpyre...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-syre/spyre-therapeutics/news/is-spyre-therapeutics-syre-fully-priced-after-its-spy772-pro","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-syre/spyre-therapeutics/news/is-spyre-therapeutics-syre-fully-priced-after-its-spy772-pro","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["SYRE","LFSC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660028408","title":"Glenmark Wins U.S. FDA Nod for Generic Flonase Nasal Spray","url":"https://stock-news.laohu8.com/highlight/detail?id=2660028408","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660028408?lang=en_us&edition=fundamental","pubTime":"2026-08-20 12:43","pubTimestamp":1787200984,"startTime":"0","endTime":"0","summary":"Glenmark Pharmaceuticals Limited ( ($IN:GLENMARK) ) just unveiled an announcement. Glenmark Pharmaceuticals has secured U.S. FDA approval for its F...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/glenmark-wins-u-s-fda-nod-for-generic-flonase-nasal-spray?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/glenmark-wins-u-s-fda-nod-for-generic-flonase-nasal-spray?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IYH","BK4585","PSCH","RSPH","TECB","LABU","GNMX","TBXU","MRNX","GDOC","NVIB","PINK","BMED","LFSC","FRTY","IEIH","BBP","BK4588","SYNB","MEDI","IBB","IDNA","XLVX","MRNY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660479247","title":"Telix outlines H1 2026 progress in radiopharmaceutical and precision medicine units","url":"https://stock-news.laohu8.com/highlight/detail?id=2660479247","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660479247?lang=en_us&edition=fundamental","pubTime":"2026-08-20 07:29","pubTimestamp":1787182181,"startTime":"0","endTime":"0","summary":"The latest update is out from Telix Pharmaceuticals ( ($AU:TLX) ). Telix Pharmaceuticals released an interim H1 2026 results presentation outlining...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/telix-outlines-h1-2026-progress-in-radiopharmaceutical-and-precision-medicine-units?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/telix-outlines-h1-2026-progress-in-radiopharmaceutical-and-precision-medicine-units?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["HELX","BK4585","MEDX","JDOC","GNMX","GDOC","WDNA","BMED","LFSC","HTEC","PBE","GNOM","TLX","BK4588","TMAT","XT","FDIF","BK4139","IBB","IDNA","SYNB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660478716","title":"Travere Therapeutics Director Gary A. Lyons Disposes of USD 629,150 in Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2660478716","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660478716?lang=en_us&edition=fundamental","pubTime":"2026-08-20 04:05","pubTimestamp":1787169946,"startTime":"0","endTime":"0","summary":"Travere Therapeutics director Gary A. Lyons disposes of USD 629,150 in common sharesTravere Therapeutics director Gary A. Lyons sold 10,000 shares on Aug. 17-18 at about $62.53-$64.16.Sales followed o","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260819:nNDL3ZcbDS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Travere Therapeutics Director Gary A. Lyons Disposes of USD 629,150 in Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TVTX","BK4139","LFSC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660252964","title":"Femasys announces FDA approval of FemBloc modular premarket approval application","url":"https://stock-news.laohu8.com/highlight/detail?id=2660252964","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660252964?lang=en_us&edition=fundamental","pubTime":"2026-08-19 21:16","pubTimestamp":1787145413,"startTime":"0","endTime":"0","summary":"Femasys (FEMY) announced that the FDA has approved the company’s modular premarket approval application pathway for FemBloc, its investigational no...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/femasys-announces-fda-approval-of-fembloc-modular-premarket-approval-application-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/femasys-announces-fda-approval-of-fembloc-modular-premarket-approval-application-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GDOC","RSPH","XLVX","BK4082","IBB","BBP","PSCH","MRNX","IEIH","LABU","SYNB","TBXU","TECB","MRNY","FEMY","IYH","MEDI","BMED","BK4539","BK4585","IDNA","FRTY","BK4584","LFSC","PINK","BK4588","GNMX","NVIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660428271","title":"Soccer-Sheffield United's Ex-Owners Winds up Company Which Bought Club","url":"https://stock-news.laohu8.com/highlight/detail?id=2660428271","media":"Reuters","labels":["policyRegulatory","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660428271?lang=en_us&edition=fundamental","pubTime":"2026-08-19 20:22","pubTimestamp":1787142120,"startTime":"0","endTime":"0","summary":"Soccer-Sheffield United's ex-owners winds up company which bought clubLONDON, Aug 19 (Reuters)-Sheffield United's former owner on Wednesday won a bid to wind up the company that in 2024 bought the sec","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260819:nL1N44F0P9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HELX","BK4585","LU0320765992.SGD","PTH","LU0109394709.USD","BK4551","GNOM","LFSC","GH","GNMX","LU0889565916.HKD","BK4588","EKG","FFOX","GDOC","BK4535","BK4196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660970474","title":"Guardant Health Director Tariq Musa Disposes of 116 Common Shares Worth $18,148.2","url":"https://stock-news.laohu8.com/highlight/detail?id=2660970474","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660970474?lang=en_us&edition=fundamental","pubTime":"2026-08-19 06:15","pubTimestamp":1787091347,"startTime":"0","endTime":"0","summary":"Guardant Health director Tariq Musa disposes of 116 common shares worth $18,148.2Guardant Health director Tariq Musa sold 116 common shares on Aug. 17 at USD 156.45.The sale cut his directly held stak","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260818:nNDLbdy8Tn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Guardant Health Director Tariq Musa Disposes of 116 Common Shares Worth $18,148.2","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4551","BK4588","GNOM","HELX","BK4535","LU0109394709.USD","BK4196","LFSC","PTH","EKG","GH","LU0320765992.SGD","LU0889565916.HKD","GNMX","GDOC","FFOX","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660595493","title":"Amylyx Phase 3 data support FDA approval, says Citi","url":"https://stock-news.laohu8.com/highlight/detail?id=2660595493","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660595493?lang=en_us&edition=fundamental","pubTime":"2026-08-18 22:05","pubTimestamp":1787061936,"startTime":"0","endTime":"0","summary":"Citi says Amylyx’s (AMLX) avexitide showed a “highly differentiated” profile in the Phase 3 LUCIDITY study, a 78 participant, placebo-controlled tr...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/amylyx-phase-3-data-support-fda-approval-says-citi-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/amylyx-phase-3-data-support-fda-approval-says-citi-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IBB","IDNA","IEIH","BK4585","TECB","PINK","MRNX","SYNB","LFSC","MEDI","RSPH","IYH","LABU","BBP","FRTY","MRNY","BK4007","NVIB","XLVX","GNMX","BMED","AMLX","BK4588","GDOC","TBXU","PSCH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660495332","title":"Guardant Health (GH) Back In Focus As New Approvals Put Valuation To The Test","url":"https://stock-news.laohu8.com/highlight/detail?id=2660495332","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660495332?lang=en_us&edition=fundamental","pubTime":"2026-08-18 21:26","pubTimestamp":1787059570,"startTime":"0","endTime":"0","summary":"Why Guardant Health Stock Is Back on Investors’ Radar\nGuardant Health (GH) moved into focus after several Q2 2026 developments, including FDA approval of an updated Guardant360 liquid biopsy test and new American Cancer Society support for its Shield colorectal cancer screening.\nThese clinical and guideline milestones arrived alongside stronger than expected Q1 results related to test volume and coverage trends. This provided investors with fresh information on how the company’s product...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6032000-choice2-main-header/1585186864566","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6032000-choice2-main-header/1585186864566"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nasdaq-gh/guardant-health/news/guardant-health-gh-back-in-focus-as-new-approvals-put-valuat","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nasdaq-gh/guardant-health/news/guardant-health-gh-back-in-focus-as-new-approvals-put-valuat","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU0320765992.SGD","BK4535","LFSC","EKG","LU0109394709.USD","BK4551","FFOX","HELX","GH","PTH","BK4588","BK4585","GNOM","LU0889565916.HKD","GNMX","GDOC","BK4196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660461015","title":"Genprex selects manufacturing organization for diabetes gene therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2660461015","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660461015?lang=en_us&edition=fundamental","pubTime":"2026-08-18 19:10","pubTimestamp":1787051418,"startTime":"0","endTime":"0","summary":"Genprex (GNPX) has entered into a development and manufacturing agreement with a U.S. based clinical and commercial Contract Development and Manufa...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/genprex-selects-manufacturing-organization-for-diabetes-gene-therapy-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/genprex-selects-manufacturing-organization-for-diabetes-gene-therapy-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SYNB","BK4139","CNCR","FBT","LFSC","BK4588","GNOM","GNPX","IBB","IBBQ","TBXU","BK4585","EES"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660489461","title":"Has Cogent Biosciences (COGT) Run Too Far After Wider Losses?","url":"https://stock-news.laohu8.com/highlight/detail?id=2660489461","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660489461?lang=en_us&edition=fundamental","pubTime":"2026-08-17 17:23","pubTimestamp":1786958611,"startTime":"0","endTime":"0","summary":"Cogent Biosciences (COGT) recently reported second quarter 2026 results, with a net loss of US$96.41 million compared with US$73.53 million a year earlier. For the first half, net loss reached US$193.76 million versus US$145.52 million.\nSee our latest analysis for Cogent Biosciences.\nThe earnings update arrives after a very strong 1 year total shareholder return of 213.21%. The 90 day share price return of 21.38% and more recent 7 day share price decline of 8.67% suggest some momentum has...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cogt/cogent-biosciences/news/has-cogent-biosciences-cogt-run-too-far-after-wider-losses","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cogt/cogent-biosciences/news/has-cogent-biosciences-cogt-run-too-far-after-wider-losses","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["CANC","LFSC","BK4139","COGT","BK4505"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":9,"pageCount":1,"totalSize":177,"code":"91000000","status":"200"}]}}